ADXS Advaxis's ADXS-cHER2 Immunotherapy Continues to Demonstrate Significantly Prolonged Survival in C... http://finance.yahoo.com/news/advaxiss-adxs-cher2-immunotherapy-continues-113000712.html?soc_src=mediacontentstory